Peter Hofland

Journalist & Medical Writer/Editor - R&D/Life #Science #Biotech #Pharma. Managing Partner InPress Media Group & Sunvalley Communication

[Peter Hofland @hofland]

https://t.co/12HWOjLnyT

[Peter Hofland @hofland]

https://t.co/upn1KXSiIB

[Lonza @LonzaGroup]

Lonza will be exhibiting at CPHI North America from 25-27 April. Visit our team at Booth #459 to discuss your project requirements. Two of our scientists will also be speaking about PBPK modeling at the conference on the Tuesday morning.

#LonzaSM #SmallMolecules #WeWorkAsOne

[ADC Review @ADCReview]

https://t.co/jZ5gaGgHVe
https://t.co/2tJ3AJCVf9

[Peter Hofland @hofland]

Help make it happen for The Onco’Zine Brief with Peter Hofland on @indiegogo https://t.co/1qK9kpY21g

[Peter Hofland @hofland]

Learn the story behind "The Onco’Zine Brief with Peter Hofland" and help us meet our goal. @indiegogo https://t.co/8gOFSKKDE7

[Peter Hofland @hofland]

A Progress Check on Hospital Price Transparency
https://t.co/hrlhbad9xf

#hospital #pricetransparancy #healthcarecosts

[Peter Hofland @hofland]

First Patient Dosed in Phase 1/1b Dose Escalation/Expansion Study of PRGN-3007 in Advanced ROR1+

https://t.co/aXa11cky4x

#cancer #ROR1 #CancerResearch #drugdevelopment

[Peter Hofland @hofland]

Prevention is the Best Medicine: Keeping You and Your Family Safe from Cancer (by ByJennifer Truscott and Clay Anderson, MD, FACP, FAAHPM) https://t.co/EYmPy5FB4C

[Peter Hofland @hofland]

Australian Study Shows COVID-19 Vaccine Induces Strong T-cell Response in Hematology Patients
https://t.co/mSf2AKksCw

#hematology #Cancer #CancerResearch #COVID19

[Peter Hofland @hofland]

Retifanlimab (Zynyz™) Approved for Treatment of Metastatic/Recurrent Locally Advanced Merkel Cell Carcinoma
https://t.co/SK1qNNBv7q

#merkelcellcarcinoma @Incyte @MacroGenics

[Peter Hofland @hofland]

Researchers Identify Potential Targets to Overcome Treatment Resistance in Aggressive Breast Cancer https://t.co/fNKPLXJMEC

#CancerResearch #TNBC #Aggressivebreastcancer

[Peter Hofland @hofland]

BECOME A PATRON OF
Onco'Zine and The Onco'Zine Brief
https://t.co/asRk0i8LYp

[Peter Hofland @hofland]

Researchers Find Breast Tumors of Asian, Black and White Women to have Different Cellular Features
https://t.co/aFhDwGAQsl

[Peter Hofland @hofland]

Study Shows Disparities in Mesothelioma Survival due to Social Determinants and Limited Access.
https://t.co/xQEIasJUMo

[Onco'Zine - Network @OncoZine]

Researchers @hopkinskimmel found breast tumors of Asian, Black and white women had different cellular features which could be use to personalize care. (via @OncoZine Read the article here https://t.co/8NMe3Lwdyf

[Peter Hofland @hofland]

Neutrophils Identified as Major Culprits in Treatment Resistance of Pancreatic Cancer
https://t.co/jbwqw81sf2

[Peter Hofland @hofland]

Zolbetuximab Plus CAPOX Improves Survival in Select Gastric Cancers.
https://t.co/KI9JXlX0v1

[Peter Hofland @hofland]

Lung Cancer Research Foundation Signs Collaboration Agreement with Daiichi Sankyo and AstraZeneca
https://t.co/xXouaoku1H

[Peter Hofland @hofland]

Researchers @hopkinskimmel found breast tumors of Asian, Black and white women had different cellular features which could be use to personalize care. (via @OncoZine Read the article here https://t.co/CxuHVm2Ye5